Gujarat Alkali is a leading manufacturer of chlor alkali chemicals. The company manufactures and sells chemical products like caustic soda, chloromethanes, caustic flakes, chlorine gas, sodium cyanide and liquid chlorine. It is one of only two produc... More
With the acquisition of Aventis CropScience, Bayer CropScience Ltd., (formerly Bayer India) became a focused crop science company with interest in Crop Protection and Vector Control (VC) business. The company market share in the cropscience market is... More
GUJARAT ALKALIES | BAYER CROPSCIENCE | GUJARAT ALKALIES/ BAYER CROPSCIENCE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 7.1 | 32.1 | 22.2% | View Chart |
P/BV | x | 0.6 | 10.1 | 5.5% | View Chart |
Dividend Yield | % | 2.5 | 0.3 | 760.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GUJARAT ALKALIES Mar-19 |
BAYER CROPSCIENCE Mar-19 |
GUJARAT ALKALIES/ BAYER CROPSCIENCE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 792 | 4,782 | 16.6% | |
Low | Rs | 416 | 3,700 | 11.2% | |
Sales per share (Unadj.) | Rs | 430.5 | 782.3 | 55.0% | |
Earnings per share (Unadj.) | Rs | 94.0 | 69.2 | 135.8% | |
Cash flow per share (Unadj.) | Rs | 113.0 | 79.2 | 142.8% | |
Dividends per share (Unadj.) | Rs | 8.00 | 18.00 | 44.4% | |
Dividend yield (eoy) | % | 1.3 | 0.4 | 312.1% | |
Book value per share (Unadj.) | Rs | 584.9 | 548.6 | 106.6% | |
Shares outstanding (eoy) | m | 73.44 | 34.33 | 213.9% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.4 | 5.4 | 25.9% | |
Avg P/E ratio | x | 6.4 | 61.3 | 10.5% | |
P/CF ratio (eoy) | x | 5.3 | 53.6 | 10.0% | |
Price / Book Value ratio | x | 1.0 | 7.7 | 13.4% | |
Dividend payout | % | 8.5 | 26.0 | 32.7% | |
Avg Mkt Cap | Rs m | 44,358 | 145,592 | 30.5% | |
No. of employees | `000 | 1.5 | 1.1 | 130.5% | |
Total wages/salary | Rs m | 2,070 | 3,212 | 64.4% | |
Avg. sales/employee | Rs Th | 21,550.0 | 23,894.1 | 90.2% | |
Avg. wages/employee | Rs Th | 1,410.8 | 2,857.7 | 49.4% | |
Avg. net profit/employee | Rs Th | 4,704.7 | 2,113.9 | 222.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 31,614 | 26,857 | 117.7% | |
Other income | Rs m | 608 | 372 | 163.4% | |
Total revenues | Rs m | 32,222 | 27,229 | 118.3% | |
Gross profit | Rs m | 11,164 | 3,732 | 299.1% | |
Depreciation | Rs m | 1,400 | 342 | 409.3% | |
Interest | Rs m | 209 | 99 | 211.5% | |
Profit before tax | Rs m | 10,163 | 3,663 | 277.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,261 | 1,287 | 253.4% | |
Profit after tax | Rs m | 6,902 | 2,376 | 290.5% | |
Gross profit margin | % | 35.3 | 13.9 | 254.1% | |
Effective tax rate | % | 32.1 | 35.1 | 91.3% | |
Net profit margin | % | 21.8 | 8.8 | 246.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 16,101 | 20,908 | 77.0% | |
Current liabilities | Rs m | 5,080 | 9,044 | 56.2% | |
Net working cap to sales | % | 34.9 | 44.2 | 78.9% | |
Current ratio | x | 3.2 | 2.3 | 137.1% | |
Inventory Days | Days | 27 | 119 | 22.4% | |
Debtors Days | Days | 56 | 81 | 69.7% | |
Net fixed assets | Rs m | 26,077 | 3,654 | 713.7% | |
Share capital | Rs m | 734 | 343 | 214.1% | |
"Free" reserves | Rs m | 42,221 | 18,491 | 228.3% | |
Net worth | Rs m | 42,956 | 18,834 | 228.1% | |
Long term debt | Rs m | 1,846 | 0 | - | |
Total assets | Rs m | 55,310 | 29,015 | 190.6% | |
Interest coverage | x | 49.5 | 38.0 | 130.3% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.9 | 61.8% | |
Return on assets | % | 12.9 | 8.5 | 150.7% | |
Return on equity | % | 16.1 | 12.6 | 127.4% | |
Return on capital | % | 23.2 | 20.0 | 115.9% | |
Exports to sales | % | 10.8 | 3.1 | 346.0% | |
Imports to sales | % | 8.7 | 1.7 | 514.7% | |
Exports (fob) | Rs m | 3,409 | 837 | 407.2% | |
Imports (cif) | Rs m | 2,745 | 453 | 605.9% | |
Fx inflow | Rs m | 3,408 | 1,029 | 331.2% | |
Fx outflow | Rs m | 3,119 | 887 | 351.6% | |
Net fx | Rs m | 290 | 142 | 203.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,378 | 4,018 | 208.5% | |
From Investments | Rs m | -5,828 | -4,124 | 141.3% | |
From Financial Activity | Rs m | -1,358 | -791 | 171.7% | |
Net Cashflow | Rs m | 1,215 | -897 | -135.5% |
Indian Promoters | % | 46.3 | 22.4 | 206.7% | |
Foreign collaborators | % | 0.0 | 46.6 | - | |
Indian inst/Mut Fund | % | 2.1 | 11.2 | 18.7% | |
FIIs | % | 4.2 | 8.2 | 51.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 47.4 | 11.6 | 408.6% | |
Shareholders | 52,842 | 19,963 | 264.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GUJARAT ALKALIES With: VINATI ORGANICS PI INDUSTRIES ATUL BAYER CROP (I) MONSANTO INDIA
Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.
For the quarter ended June 2020, BAYER CROPSCIENCE has posted a net profit of Rs 3 bn (up 324.5% YoY). Sales on the other hand came in at Rs 12 bn (up 85.0% YoY). Read on for a complete analysis of BAYER CROPSCIENCE's quarterly results.
For the quarter ended March 2020, BAYER CROPSCIENCE has posted a net profit of Rs 315 m (up 139.5% YoY). Sales on the other hand came in at Rs 5 bn (up 256.1% YoY). Read on for a complete analysis of BAYER CROPSCIENCE's quarterly results.
For the quarter ended December 2019, GUJARAT ALKALIES has posted a net profit of Rs 598 m (down 63.1% YoY). Sales on the other hand came in at Rs 7 bn (down 19.7% YoY). Read on for a complete analysis of GUJARAT ALKALIES's quarterly results.
For the quarter ended September 2019, GUJARAT ALKALIES has posted a net profit of Rs 1 bn (down 41.4% YoY). Sales on the other hand came in at Rs 7 bn (down 9.4% YoY). Read on for a complete analysis of GUJARAT ALKALIES's quarterly results.
Here's an analysis of the annual report of GUJARAT ALKALIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GUJARAT ALKALIES. Also includes updates on the valuation of GUJARAT ALKALIES.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More